Document is current
Any future updates will be listed below
-
Authors
Liu, Zhihui
Bagchi, Sukriti
Yan, Chunhua
Hu, Ying
Blum, Gil
Ma, Anqi
Jin, Jian
Luo, Minkui
Di Bella, Sebastiano
Verona, Francesco
Appella, Ettore
Giannini, Giuseppe
Thiele, Carol J.
Veschi, Veronica
-
Funding
Funding for this research was provided by:
National Cancer Institute (NIH R35 grant GM131858)
Italian Ministry of University and Research as a part of the PNRR (M4C2-l1.3 Project PE00000019 ‘HEAL ITALIA’ CUP B73C22001250006)
Italian Ministry of University and Research as a part of the PNRR (M4C2-l1.3 Project PE00000019 ‘HEAL ITALIA’ CUP B53C22004000006)
National Cancer Institute, Center for Cancer Research (Intramural Research Program of the NIH)
AIRC (IG (24329))
Department of Molecular Medicine, Dipartimento Eccellenza Italian Ministry of Education, Universities and Research (Dipartimenti di Eccellenza – L. 232/2016)
Sapienza Università di Roma (RICERCA DI ATENEO 2024, CUP B83C25000880005)
- License Information
-
More Information
Article History
Received: 10 February 2025
Accepted: 20 October 2025
First Online: 19 December 2025
Declarations
:
: All animal experiments and procedures were approved by the Animal Care and Use Committee of the National Cancer Institute and performed in accordance with the institutional guidelines (PB-023).
: All the authors provided consent for the publication of the manuscript in the Journal of Experimental & Clinical Cancer Research .
: J.J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. The other authors declare no competing interests.The other authors declare no competing interests.
